Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMAL DIURETIC THERAPIES FOR ACUTE HEART FAILURE WITH VOLUME OVERLOAD
2024-510633-17-00Phase 3Authorised
- Sponsor
- Capital Region of Denmark
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Acute Heart Failure (AHF) comparing Metolazone strategy, Acetazolamide strategy and Placebo/saline control strategy (3 arms). Primary endpoint: Days alive and outside hospital until day 30. Planned start Apr 2024; status: authorised.
02
Drugs
metolazoneacetazolamide
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on 2024-510633-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510633-17-00.